Literature DB >> 29086333

Association Between Adipokines Levels with Inflammatory Bowel Disease (IBD): Systematic Reviews.

Nava Morshedzadeh1,2, Mehran Rahimlou3, Hamid Asadzadeh Aghdaei4, Shabnam Shahrokh4, Mohammad Reza Zali4, Parvin Mirmiran5,6.   

Abstract

BACKGROUND: A combination of genetic and environmental factors is involved in the etiology of inflammatory bowel disease (IBD). Recent studies have shown that adipocytes play a crucial role, by actively participating in systemic immune responses in IBD patients. But findings remain controversial. To the best of our knowledge, no systematic review has evaluated the roles of adipokines in IBD, considering which this systematic review was undertaken to summarize the effects of these adipokines in IBD pathogenesis.
METHODS: For this review, articles published between 1980 and 2016 were identified from the PubMed, EMBASE, Scopus, and Cochrane and Google scholar databases. Thirteen articles were ultimately selected for inclusion in this systematic review.
RESULTS: Findings of the present study indicate that some of the adipokines such as leptin, adiponectin and resistin are associated with disease severity, body composition and glucose hemostasis in IBD patients, although some of these associations are stronger than others.
CONCLUSIONS: Overall findings indicate that some adipokines may play a crucial role in IBD severity or other IBD related outcomes. Further studies are recommended to confirm the results.

Entities:  

Keywords:  Adipokines; Adiponectin; IBD; Inflammatory bowel disease; Leptin

Mesh:

Substances:

Year:  2017        PMID: 29086333     DOI: 10.1007/s10620-017-4806-5

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  39 in total

1.  Different effects of adiponectin isoforms in human monocytic cells.

Authors:  Markus Neumeier; Johanna Weigert; Andreas Schäffler; Gabriele Wehrwein; Ulf Müller-Ladner; Jürgen Schölmerich; Christian Wrede; Christa Buechler
Journal:  J Leukoc Biol       Date:  2006-01-24       Impact factor: 4.962

Review 2.  Adipokines in inflammation and metabolic disease.

Authors:  Noriyuki Ouchi; Jennifer L Parker; Jesse J Lugus; Kenneth Walsh
Journal:  Nat Rev Immunol       Date:  2011-01-21       Impact factor: 53.106

3.  Human resistin stimulates the pro-inflammatory cytokines TNF-alpha and IL-12 in macrophages by NF-kappaB-dependent pathway.

Authors:  Nirupama Silswal; Anil K Singh; Battu Aruna; Sangita Mukhopadhyay; Sudip Ghosh; Nasreen Z Ehtesham
Journal:  Biochem Biophys Res Commun       Date:  2005-09-09       Impact factor: 3.575

4.  Effects of tumor necrosis factor alpha inhibition with infliximab on lipid levels and insulin resistance in patients with inflammatory bowel disease.

Authors:  Ioannis E Koutroubakis; Pantelis Oustamanolakis; Niki Malliaraki; Konstantinos Karmiris; Ioannis Chalkiadakis; Emmanouel Ganotakis; Nikolaos Karkavitsas; Elias A Kouroumalis
Journal:  Eur J Gastroenterol Hepatol       Date:  2009-03       Impact factor: 2.566

5.  Serum Visfatin Levels in Ulcerative Colitis.

Authors:  Serkan Dogan; Kadri Guven; Mehmet Celikbilek; Kemal Deniz; Berkay Saraymen; Sebnem Gursoy
Journal:  J Clin Lab Anal       Date:  2015-12-14       Impact factor: 2.352

6.  Dysregulation of the expression and secretion of inflammation-related adipokines by hypoxia in human adipocytes.

Authors:  Bohan Wang; I Stuart Wood; Paul Trayhurn
Journal:  Pflugers Arch       Date:  2007-07-03       Impact factor: 3.657

7.  Impact of infliximab on serum leptin levels in patients with Crohn's disease.

Authors:  Denis Franchimont; Sandrine Roland; Thierry Gustot; Eric Quertinmont; Youssef Toubouti; Marie-Christine Gervy; Jacques Deviere; Andre Van Gossum
Journal:  J Clin Endocrinol Metab       Date:  2005-03-22       Impact factor: 5.958

Review 8.  Leptin, resistin and visfatin: the missing link between endocrine metabolic disorders and immunity.

Authors:  Ebtesam A Al-Suhaimi; Adeeb Shehzad
Journal:  Eur J Med Res       Date:  2013-05-01       Impact factor: 2.175

9.  Expression and function of visfatin (Nampt), an adipokine-enzyme involved in inflammatory pathways of osteoarthritis.

Authors:  Marie-Charlotte Laiguillon; Xavier Houard; Carole Bougault; Marjolaine Gosset; Geoffroy Nourissat; Alain Sautet; Claire Jacques; Francis Berenbaum; Jérémie Sellam
Journal:  Arthritis Res Ther       Date:  2014-01-31       Impact factor: 5.156

Review 10.  Adipose tissue immune response: novel triggers and consequences for chronic inflammatory conditions.

Authors:  Giorgio Ghigliotti; Chiara Barisione; Silvano Garibaldi; Patrizia Fabbi; Claudio Brunelli; Paolo Spallarossa; Paola Altieri; Gianmarco Rosa; Giovanni Spinella; Domenico Palombo; Razvan Arsenescu; Violeta Arsenescu
Journal:  Inflammation       Date:  2014-08       Impact factor: 4.092

View more
  9 in total

1.  Bariatric Surgery Is a Safe and Effective Option for Patients with Inflammatory Bowel Diseases: A Case Series and Systematic Review of the Literature.

Authors:  Joshua L Hudson; Edward L Barnes; Hans H Herfarth; Kim L Isaacs; Animesh Jain
Journal:  Inflamm Intest Dis       Date:  2019-03-19

2.  Circulating levels of WISP-1 (Wnt1-inducible signaling pathway protein 1) and other selected adipokines in children with inflammatory bowel disease.

Authors:  E Karásková; V Kubickova; M Velganova-Veghova; M Geryk; H Foltenova; D Karasek
Journal:  Physiol Res       Date:  2022-04-11       Impact factor: 2.139

Review 3.  Peroxisome Proliferator-Activated Receptors: Experimental Targeting for the Treatment of Inflammatory Bowel Diseases.

Authors:  Juan Decara; Patricia Rivera; Antonio Jesús López-Gambero; Antonia Serrano; Francisco Javier Pavón; Elena Baixeras; Fernando Rodríguez de Fonseca; Juan Suárez
Journal:  Front Pharmacol       Date:  2020-05-27       Impact factor: 5.810

Review 4.  Role of Obesity, Mesenteric Adipose Tissue, and Adipokines in Inflammatory Bowel Diseases.

Authors:  Jan Bilski; Agnieszka Mazur-Bialy; Dagmara Wojcik; Marcin Surmiak; Marcin Magierowski; Zbigniew Sliwowski; Robert Pajdo; Slawomir Kwiecien; Aleksandra Danielak; Agata Ptak-Belowska; Thomas Brzozowski
Journal:  Biomolecules       Date:  2019-11-26

Review 5.  Role of Adipose Tissue in Inflammatory Bowel Disease.

Authors:  Eva Karaskova; Maria Velganova-Veghova; Milos Geryk; Hana Foltenova; Veronika Kucerova; David Karasek
Journal:  Int J Mol Sci       Date:  2021-04-19       Impact factor: 5.923

Review 6.  Impact of Obesity on the Course of Management of Inflammatory Bowel Disease-A Review.

Authors:  Agata Michalak; Beata Kasztelan-Szczerbińska; Halina Cichoż-Lach
Journal:  Nutrients       Date:  2022-09-25       Impact factor: 6.706

7.  Adiponectin Expression Is Modulated by Long-Term Physical Activity in Adult Patients Affected by Cystic Fibrosis.

Authors:  Rita Polito; Ersilia Nigro; Ausilia Elce; Maria Ludovica Monaco; Paola Iacotucci; Vincenzo Carnovale; Marika Comegna; Monica Gelzo; Federica Zarrilli; Gaetano Corso; Giuseppe Castaldo; Aurora Daniele
Journal:  Mediators Inflamm       Date:  2019-09-09       Impact factor: 4.711

8.  The Clinical Importance of 21-Day Combined Parenteral and Enteral Nutrition in Active Inflammatory Bowel Disease Patients.

Authors:  Dorota Mańkowska-Wierzbicka; Jacek Karczewski; Ewelina Swora-Cwynar; Agnieszka Dobrowolska; Marta Stelmach-Mardas
Journal:  Nutrients       Date:  2019-09-18       Impact factor: 5.717

Review 9.  What was First, Obesity or Inflammatory Bowel Disease? What Does the Gut Microbiota Have to Do with It?

Authors:  Sara Jarmakiewicz-Czaja; Aneta Sokal; Rafał Filip
Journal:  Nutrients       Date:  2020-10-08       Impact factor: 5.717

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.